Journal
JOURNAL OF CLINICAL MEDICINE
Volume 12, Issue 17, Pages -Publisher
MDPI
DOI: 10.3390/jcm12175539
Keywords
BCMA; Bispecific antibodies; CAR-T cell therapy; relapsed multiple myeloma; BiTEs; ADCs
Categories
Ask authors/readers for more resources
Anti-B-cell maturation antigen therapies have shown promising results in relapsed refractory multiple myeloma, but severe side effects pose a risk to patients. This review focuses on the most common complications post-BCMA therapy, discussing risk factors, pathogenesis, clinical features, and prevention and treatment strategies. FDA-approved agents for adult RRMM patients were analyzed to outline stepwise management of complications.
Anti-B-cell maturation antigen therapies consisting of bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T cells have shown promising results in relapsed refractory multiple myeloma (RRMM). However, the severe side effects include cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cytopenia(s), infections, hemophagocytic lymphohistiocytosis, and organ toxicity, which could sometimes be life-threatening. This review focuses on these most common complications post-BCMA therapy. We discussed the risk factors, pathogenesis, clinical features associated with these complications, and how to prevent and treat them. We included four original studies for this focused review. All four agents (idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, belantamab mafodotin) have received FDA approval for adult RRMM patients. We went through the FDA access data packages of the approved agents to outline stepwise management of the complications for better patient outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available